Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)

References

• Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, et al. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11(5):329–341. doi: 10.1038/nrm2882
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol. 2012;13(3):195–203. doi: 10.1038/nrm3290
   PubMed Web of Science ®Google Scholar
• Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28(6):1075–1083. doi: 10.1200/JCO.2009.25.3641
   PubMed Web of Science ®Google Scholar
• Sanchez VE, Nichols C, Kim HN, et al. Targeting PI3K signaling in acute lymphoblastic leukemia. Int J Mol Sci. 2019;20(2):412. doi: 10.3390/ijms20020412
   PubMed Web of Science ®Google Scholar
• Ward S, Sotsios Y, Dowden J, et al. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem Biol. 2003;10(3):207–213. doi: 10.1016/s1074-5521(03)00048-6
   PubMed Web of Science ®Google Scholar
• Mishra R, Patel H, Alanazi S, et al. PI3K inhibitors in cancer: Clinical implications and adverse effects. Int J Mol Sci. 2021;22(7):3464. doi: 10.3390/ijms22073464
   PubMed Web of Science ®Google Scholar
• Sabbah DA, Brattain MG, Zhong HA. Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: which way shall we go? Curr Med Chem. 2011;18(36):5528–5544. doi: 10.2174/092986711798347298
   PubMed Web of Science ®Google Scholar
• Sabbah DA, Hu J, Zhong HA. Advances in the development of class i phosphoinositide 3-kinase (PI3K). CurrTop Med Chem. 2016;16(3):1413–1426. doi: 10.2174/1568026615666150915115823
   Google Scholar
• Sabbah DA, Hajjo R, Bardaweel SK, et al. Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016-2020). Expert Opin Ther Pat. 2021;31(10):877–892.
   PubMed Web of Science ®Google Scholar
• Knight ZA, Gonzalez B, Feldman ME, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006;125(4):733–747.
   PubMed Web of Science ®Google Scholar
• Jia S, Roberts TM, Zhao JJ. Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol. 2009;21(2):199–208. doi: 10.1016/j.ceb.2008.12.007
   PubMed Web of Science ®Google Scholar
• Long HZ, Cheng Y, Zhou ZW, et al. PI3K/AKT signal pathway: A target of natural products in the prevention and treatment of Alzheimer’s disease and Parkinson’s disease. Front Pharmacol. 2021;12:648636. doi: 10.3389/fphar.2021.648636
   PubMed Web of Science ®Google Scholar
• Xie Y, Shi X, Sheng K, et al. PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia (Review). Mol Med Rep. 2019;19(2):783–791.
   PubMed Web of Science ®Google Scholar
• Shorning BY, Dass MS, Smalley MJ, et al. The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci. 2020;21(12):4507. doi: 10.3390/ijms21124507
   PubMed Web of Science ®Google Scholar
• Stefani C, Miricescu D, Stanescu S II, et al. Growth factors, PI3K/AKT/mTOR and MAPK signaling pathways in colorectal cancer pathogenesis: where are we now? Int J Mol Sci. 2021;22(19):10260.
   PubMed Web of Science ®Google Scholar
• Sun K, Luo J, Guo J, et al. The PI3K/AKT/mTOR signaling pathway in osteoarthritis: a narrative review. Osteoarthr Cartil. 2020;28(4):400–409. doi: 10.1016/j.joca.2020.02.027
   PubMed Web of Science ®Google Scholar
• Barra F, Evangelisti G, Ferro Desideri L, et al. Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer. Expert Opin Investig Drugs. 2019;28(2):131–142. doi: 10.1080/13543784.2018.1558202
   PubMed Web of Science ®Google Scholar
• Stallone G, Infante B, Prisciandaro C, et al. mTOR and aging: an old fashioned dress. Int J Mol Sci. 2019;20(11):2774. doi: 10.3390/ijms20112774
   PubMed Web of Science ®Google Scholar
• Peng Y, Wang Y, Zhou C, et al. PI3K/Akt/mTOR pathway and its role in cancer therapeutics: Are we making headway? Front Oncol. 2022;12:819128. doi: 10.3389/fonc.2022.819128
   PubMed Web of Science ®Google Scholar
• Akbarzadeh M, Mihanfar A, Akbarzadeh S, et al. Crosstalk between miRNA and PI3K/AKT/mTOR signaling pathway in cancer. Life Sci. 2021;285:119984. doi: 10.1016/j.lfs.2021.119984
   PubMed Web of Science ®Google Scholar
• Fruman DA, Chiu H, Hopkins BD, et al. The PI3K pathway in human disease. Cell. 2017;170(4):605–635. doi: 10.1016/j.cell.2017.07.029
   PubMed Web of Science ®Google Scholar
• Faes S, Dormond O. PI3K and AKT: unfaithful partners in cancer. Int J Mol Sci. 2015;16(9):21138–21152. doi: 10.3390/ijms160921138
   PubMed Web of Science ®Google Scholar
• Trautmann M, Cyra M, Isfort I, et al. Phosphatidylinositol-3-kinase (PI3K)/Akt signaling is functionally essential in myxoid liposarcoma. Mol Cancer Ther. 2019;18(4):834–844. doi: 10.1158/1535-7163.MCT-18-0763
   PubMed Web of Science ®Google Scholar
• Shi X, Wang J, Lei Y, et al. Research progress on the PI3K/AKT signaling pathway in gynecological cancer (review). Mol Med Rep. 2019;19(6):4529–4535. doi: 10.3892/mmr.2019.10121
   PubMed Web of Science ®Google Scholar
• Chen H, Gao J, Du Z, et al. Expression of factors and key components associated with the PI3K signaling pathway in colon cancer. Oncol Lett. 2018;15(4):5465–5472. doi: 10.3892/ol.2018.8044
   PubMed Web of Science ®Google Scholar
• Vidal S, Bouzaher YH, El Motiam A, et al. Overview of the regulation of the class IA PI3K/AKT pathway by SUMO. Semin Cell Dev Biol. 2022;132:51–61. doi: 10.1016/j.semcdb.2021.10.012
   PubMed Web of Science ®Google Scholar
• He Y, Sun MM, Zhang GG, et al. Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6(1):425. doi: 10.1038/s41392-021-00828-5
   PubMed Web of Science ®Google Scholar
• Zhou Y, Li S, Li J, et al. Effect of microRNA-135a on cell proliferation, migration, invasion, apoptosis and tumor angiogenesis through the IGF-1/PI3K/Akt signaling pathway in non-small cell lung cancer. Cell Physiol Biochem. 2017;42(4):1431–1446. doi: 10.1159/000479207
   PubMedGoogle Scholar
• Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol. 2018;15(5):273–291. doi: 10.1038/nrclinonc.2018.28
   PubMed Web of Science ®Google Scholar
• Xue C, Li G, Lu J, et al. Crosstalk between circRnas and the PI3K/AKT signaling pathway in cancer progression. Signal Transduct Target Ther. 2021 Nov 24;6(1):400. doi: 10.1038/s41392-021-00788-w
   PubMed Web of Science ®Google Scholar
• Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999;21(1):99–102. doi: 10.1038/5042
   PubMed Web of Science ®Google Scholar
• Samuels Y, Diaz LA, Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005;7(6):561–573. doi: 10.1016/j.ccr.2005.05.014
   PubMed Web of Science ®Google Scholar
• Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004;3(10):1221–1224. doi: 10.4161/cc.3.10.1164
   PubMed Web of Science ®Google Scholar
• Samuels Y, Wang ZH, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554. doi: 10.1126/science.1096502
   PubMed Web of Science ®Google Scholar
• Zhang M, Jang H, Nussinov R. PI3K driver mutations: a biophysical membrane-centric perspective. Cancer Res. 2021 Jan 15;81(2):237–247. doi: 10.1158/0008-5472.CAN-20-0911
   PubMed Web of Science ®Google Scholar
• Iida M, Harari PM, Wheeler DL, et al. Targeting AKT/PKB to improve treatment outcomes for solid tumors. Mutat Res. 2020;819-820:111690. doi: 10.1016/j.mrfmmm.2020.111690
   PubMed Web of Science ®Google Scholar
• Liu X, Zhou Q, Hart JR, et al. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα. Proc Natl Acad Sci, USA. 2022;119(46):e2215621119. doi: 10.1073/pnas.2215621119
   PubMed Web of Science ®Google Scholar
• Fusco N, Malapelle U, Fassan M, et al. PIK3CA mutations as a molecular target for hormone receptor-positive, HER2-negative metastatic breast cancer. Front Oncol. 2021;11:644737. doi: 10.3389/fonc.2021.644737
   PubMed Web of Science ®Google Scholar
• Liu R, Chen Y, Liu G, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11(9):797. doi: 10.1038/s41419-020-02998-6
   PubMed Web of Science ®Google Scholar
• Hajjo R, Sabbah DA, Abusara OH, et al. Targeting human proteins for antiviral drug discovery and repurposing efforts: a focus on protein kinases. Viruses. 2023;15(2):568. doi: 10.3390/v15020568
   PubMed Web of Science ®Google Scholar
• Matsuda S, Ikeda Y, Murakami M, et al. Roles of PI3K/AKT/GSK3 pathway involved in psychiatric illnesses. Diseases. 2019;7(1):22. doi: 10.3390/diseases7010022
   PubMedGoogle Scholar
• Razani E, Pourbagheri-Sigaroodi A, Safaroghli-Azar A, et al. The PI3K/Akt signaling axis in Alzheimer’s disease: a valuable target to stimulate or suppress? Cell Stress Chaperones. 2021;26(6):871–887. doi: 10.1007/s12192-021-01231-3
   PubMed Web of Science ®Google Scholar
• Kumar M, Bansal N. Implications of phosphoinositide 3-kinase-akt (PI3K-Akt) pathway in the pathogenesis of Alzheimer’s disease. Mol Neurobiol. 2022;59(1):354–385. doi: 10.1007/s12035-021-02611-7
   PubMed Web of Science ®Google Scholar
• Curtis D, Bandyopadhyay S. Mini-review: role of the PI3K/Akt pathway and tyrosine phosphatases in Alzheimer’s disease susceptibility. Ann Hum Genet. 2021;85(1):1–6. doi: 10.1111/ahg.12410
   PubMed Web of Science ®Google Scholar
• Clarivate. Introducing cortellis drug discovery intelligence [cited 2023 Jul 25]. Available from: https://clarivate.com/cortellis/campaigns/introducing-cortellis-drug-discovery-intelligence/#Clarivate
   Google Scholar
• Hopkins BD, Goncalves MD, Cantley LC. Insulin-PI3K signalling: an evolutionarily insulated metabolic driver of cancer. Nat Rev Endocrinol. 2020;16(5):276–283. doi: 10.1038/s41574-020-0329-9
   PubMed Web of Science ®Google Scholar
• Donato J Jr., Frazão R, Elias CF. The PI3K signaling pathway mediates the biological effects of leptin. Arq Bras Endocrinol Metabol. 2010;54(7):591–602. doi: 10.1590/s0004-27302010000700002
   PubMedGoogle Scholar
• Daragmeh J, Barriah W, Saad B, et al. Analysis of PI3K pathway components in human cancers. Oncol Lett. 2016;11(4):2913–2918. doi: 10.3892/ol.2016.4309
   PubMed Web of Science ®Google Scholar
• Zhang Z, Richmond A. The role of PI3K inhibition in the treatment of breast cancer, alone or combined with immune checkpoint inhibitors. Front Mol Biosci. 2021;8:648663. doi: 10.3389/fmolb.2021.648663
   PubMed Web of Science ®Google Scholar
• Sala V, Della Sala A, Ghigo A, et al. Roles of phosphatidyl inositol 3 kinase gamma (PI3Kγ) in respiratory diseases. Cell Stress. 2021;5(4):40–51. doi: 10.15698/cst2021.04.246
   PubMedGoogle Scholar
• Rascio F, Spadaccino F, Rocchetti MT, et al. The pathogenic role of PI3K/AKT pathway in cancer onset and drug resistance: an updated review. Cancers (Basel). 2021;13(16):3949. doi: 10.3390/cancers13163949
   PubMed Web of Science ®Google Scholar
• Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017;169(3):381–405. doi: 10.1016/j.cell.2017.04.001
   PubMed Web of Science ®Google Scholar
• Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20(2):74–88. doi: 10.1038/s41568-019-0216-7
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Whitehead MA, Piñeiro R. Molecules in medicine mini-review: isoforms of PI3K in biology and disease. J Mol Med. 2016;94(1):5–11. doi: 10.1007/s00109-015-1352-5
   PubMed Web of Science ®Google Scholar
• Vasan N, Toska E, Scaltriti M. Overview of the relevance of PI3K pathway in HR-positive breast cancer. Ann Oncol. 2019;30(Suppl_10):x3–x11. doi: 10.1093/annonc/mdz281
   PubMedGoogle Scholar
• Yang J, Nie J, Ma X, et al. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18(1):26. doi: 10.1186/s12943-019-0954-x
   PubMed Web of Science ®Google Scholar
• Martorana F, Motta G, Pavone G, et al. AKT inhibitors: New weapons in the fight against breast cancer? Front Pharmacol. 2021;12:662232. doi: 10.3389/fphar.2021.662232
   PubMed Web of Science ®Google Scholar
• Dunn S, Eberlein C, Yu J, et al. AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors. Oncogene. 2022;41(46):5046–5060. doi: 10.1038/s41388-022-02482-9
   PubMed Web of Science ®Google Scholar
• Pazarentzos E, Giannikopoulos P, Hrustanovic G, et al. Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation. Oncogene. 2016;35(9):1198–1205. doi: 10.1038/onc.2015.173
   PubMed Web of Science ®Google Scholar
• Owusu-Brackett N, Zhao M, Akcakanat A, et al. Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss. Oncotarget. 2020;11(11):969–981. doi: 10.18632/oncotarget.27503
   PubMedGoogle Scholar
• Talwelkar SS, Mäyränpää MI, Schüler J, et al. PI3Kβ inhibition enhances ALK-inhibitor sensitivity in ALK-rearranged lung cancer. Mol Oncol. 2023;17(5):747–764. doi: 10.1002/1878-0261.13342
   PubMed Web of Science ®Google Scholar
• Tzenaki N, Andreou M, Stratigi K, et al. High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation. Faseb J. 2012;26(6):2498–2508. doi: 10.1096/fj.11-198192
   PubMed Web of Science ®Google Scholar
• Tarantelli C, Argnani L, Zinzani PL, et al. PI3Kδ inhibitors as immunomodulatory agents for the treatment of lymphoma patients. Cancers (Basel). 2021;13(21):5535. doi: 10.3390/cancers13215535
   PubMed Web of Science ®Google Scholar
• Schmid MC, Avraamides CJ, Dippold HC, et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell. 2011;19(6):715–727. doi: 10.1016/j.ccr.2011.04.016
   PubMed Web of Science ®Google Scholar
• Gonzalez E, McGraw TE. The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle. 2009;8(16):2502–2508. doi: 10.4161/cc.8.16.9335
   PubMed Web of Science ®Google Scholar
• Hinz N, Jücker M. Distinct functions of AKT isoforms in breast cancer: a comprehensive review. Cell Commun Signal. 2019;17(1):154. doi: 10.1186/s12964-019-0450-3
   PubMed Web of Science ®Google Scholar
• Chen WS, Xu PZ, Gottlob K, et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 2001;15(17):2203–2208. doi: 10.1101/gad.913901
   PubMed Web of Science ®Google Scholar
• Garofalo RS, Orena SJ, Rafidi K, et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest. 2003;112(2):197–208.
   PubMed Web of Science ®Google Scholar
• Cho H, Mu J, Kim JK, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science. 2001;292(5522):1728–1731. doi: 10.1126/science.292.5522.1728
   PubMed Web of Science ®Google Scholar
• Tschopp O, Yang ZZ, Brodbeck D, et al. Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. Development. 2005;132(13):2943–2954.
   PubMed Web of Science ®Google Scholar
• Peng XD, Xu PZ, Chen ML, et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev. 2003;17(11):1352–1365. doi: 10.1101/gad.1089403
   PubMed Web of Science ®Google Scholar
• Kim J, Guan KL. mTOR as a central hub of nutrient signalling and cell growth. Nat Cell Biol. 2019;21(1):63–71. doi: 10.1038/s41556-018-0205-1
   PubMed Web of Science ®Google Scholar
• Oleksak P, Nepovimova E, Chrienova Z, et al. Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021). Eur J Med Chem. 2022;238:114498. doi: 10.1016/j.ejmech.2022.114498
   PubMed Web of Science ®Google Scholar
• Yi KH, Lauring J. Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity. Oncotarget. 2016;7(4):4241–4251. doi: 10.18632/oncotarget.6648
   PubMedGoogle Scholar
• Liu T, Zhu J, Du W, et al. AKT2 drives cancer progression and is negatively modulated by miR-124 in human lung adenocarcinoma. Respir Res. 2020;21(1):227. doi: 10.1186/s12931-020-01491-0
   PubMed Web of Science ®Google Scholar
• Pereira L, Horta S, Mateus R, et al. Implications of Akt2/Twist crosstalk on breast cancer metastatic outcome. Drug Discov Today. 2015;20(9):1152–1158. doi: 10.1016/j.drudis.2015.06.010
   PubMed Web of Science ®Google Scholar
• Sahlberg SH, Gustafsson AS, Pendekanti PN, et al. The influence of AKT isoforms on radiation sensitivity and DNA repair in colon cancer cell lines. Tumour Biol. 2014;35(4):3525–3534. doi: 10.1007/s13277-013-1465-9
   PubMedGoogle Scholar
• Buikhuisen JY, Gomez Barila PM, Torang A, et al. AKT3 expression in mesenchymal colorectal cancer cells drives growth and is associated with epithelial-mesenchymal transition. Cancers (Basel). 2021;13(4):801. doi: 10.3390/cancers13040801
   PubMed Web of Science ®Google Scholar
• Takahashi H, Rokudai S, Kawabata-Iwakawa R, et al. AKT3 is a novel regulator of cancer-associated fibroblasts in head and neck squamous cell carcinoma. Cancers (Basel). 2021;13(6):1233. doi: 10.3390/cancers13061233
   PubMed Web of Science ®Google Scholar
• Chang CZ, Wu SC, Chang CM, et al. Arctigenin, a potent ingredient of Arctium lappa L. induces endothelial nitric oxide synthase and attenuates subarachnoid hemorrhage-induced vasospasm through PI3K/Akt pathway in a rat model. Biomed Res Int. 2015;2015:490209. doi: 10.1155/2015/490209
   PubMed Web of Science ®Google Scholar
• Yu H, Lin L, Zhang Z, et al. Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct Target Ther. 2020;5(1):209. doi: 10.1038/s41392-020-00312-6
   PubMed Web of Science ®Google Scholar
• Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer. 2013;12(1):86. doi: 10.1186/1476-4598-12-86
   PubMed Web of Science ®Google Scholar
• Karar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci. 2011;4:51. doi: 10.3389/fnmol.2011.00051
   PubMed Web of Science ®Google Scholar
• Jafari M, Ghadami E, Dadkhah T, et al. PI3k/AKT signaling pathway: erythropoiesis and beyond. J Cell Physiol. 2019;234(3):2373–2385. doi: 10.1002/jcp.27262
   PubMed Web of Science ®Google Scholar
• Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. Semin Cancer Biol. 2019;59:147–160. doi: 10.1016/j.semcancer.2019.05.012
   PubMed Web of Science ®Google Scholar
• Ghoneum A, Said N. PI3K-AKT-mTOR and NFκB pathways in ovarian cancer: implications for targeted therapeutics. Cancers (Basel). 2019;11(7):949. doi: 10.3390/cancers11070949
   PubMed Web of Science ®Google Scholar
• Deng J, Bai X, Feng X, et al. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression. BMC Cancer. 2019;19(1):618. doi: 10.1186/s12885-019-5824-9
   PubMedGoogle Scholar
• Mabuchi S, Kuroda H, Takahashi R, et al. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol Oncol. 2015;137(1):173–179. doi: 10.1016/j.ygyno.2015.02.003
   PubMed Web of Science ®Google Scholar
• Citi V, Del Re M, Martelli A, et al. Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro. Cancer Chemother Pharmacol. 2018;81(4):745–754. doi: 10.1007/s00280-018-3543-6
   PubMed Web of Science ®Google Scholar
• Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68(15):6084–6091. doi: 10.1158/0008-5472.CAN-07-6854
   PubMed Web of Science ®Google Scholar
• Hafsi S, Pezzino FM, Candido S, et al. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Int J Oncol. 2012;40(3):639–644. doi: 10.3892/ijo.2011.1312
   PubMed Web of Science ®Google Scholar
• Braglia L, Zavatti M, Vinceti M, et al. Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: still a potential druggable target?. Biochim Biophys Acta Mol Cell Res. 2020;1867(9):118731. doi: 10.1016/j.bbamcr.2020.118731
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Perry MWD, Brown JR, et al. PI3K inhibitors are finally coming of age. Nat Rev Drug Discov. 2021;20(10):741–769. doi: 10.1038/s41573-021-00209-1
   PubMed Web of Science ®Google Scholar
• Jiang N, Dai Q, Su X, et al. Role of PI3K/AKT pathway in cancer: the framework of malignant behavior. Mol Biol Rep. 2020;47(6):4587–4629. doi: 10.1007/s11033-020-05435-1
   PubMed Web of Science ®Google Scholar
• Zhang M, Jang H, Nussinov R. PI3K inhibitors: review and new strategies. Chem Sci. 2020;11(23):5855–5865. doi: 10.1039/d0sc01676d
   PubMed Web of Science ®Google Scholar
• Meng D, He W, Zhang Y, et al. Development of PI3K inhibitors: Advances in clinical trials and new strategies (Review). Pharmacol Res. 2021;173:105900. doi: 10.1016/j.phrs.2021.105900
   PubMed Web of Science ®Google Scholar
• Fuso P, Muratore M, D’Angelo T, et al. PI3K inhibitors in advanced breast cancer: The past, the present, new challenges and future perspectives. Cancers. 2022;14(9):2161. doi: 10.3390/cancers14092161
   PubMed Web of Science ®Google Scholar
• Durrant TN, Hers I. PI3K inhibitors in thrombosis and cardiovascular disease. Clin Transl Med. 2020;9(1):8. doi: 10.1186/s40169-020-0261-6
   PubMed Web of Science ®Google Scholar
• Zhu J, Li K, Yu L, et al. Targeting phosphatidylinositol 3-kinase gamma (PI3Kγ): discovery and development of its selective inhibitors. Med Res Rev. 2021;41(3):1599–1621. doi: 10.1002/med.21770
   PubMed Web of Science ®Google Scholar
• Occhiuzzi MA, Lico G, Ioele G, et al. Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents. Eur J Med Chem. 2023;246:114971. doi: 10.1016/j.ejmech.2022.114971
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Rodon J, Serra V, et al. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther. 2014;13(5):1021–1031. doi: 10.1158/1535-7163.MCT-13-0639
   PubMed Web of Science ®Google Scholar
• Wu X, Xu Y, Liang Q, et al. Recent advances in dual PI3K/mTOR inhibitors for tumour treatment. Front Pharmacol. 2022;13:875372. doi: 10.3389/fphar.2022.875372
   PubMedGoogle Scholar
• Das D, Wang J, Hong J. Next-generation kinase inhibitors targeting specific biomarkers in non-small cell lung cancer (NSCLC): a recent overview. ChemMedchem. 2021 Aug 19;16(16):2459–2479. doi: 10.1002/cmdc.202100166
   PubMed Web of Science ®Google Scholar
• Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682–690. doi: 10.1038/nchembio.118
   PubMed Web of Science ®Google Scholar
• Hajjo R, Setola V, Roth BL, et al. Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers. J Med Chem. 2012;55(12):5704–5719. doi: 10.1021/jm2011657
   PubMed Web of Science ®Google Scholar
• STRING| Protein-Protein Interaction Networks| Functional Enrichment Analysis. [cited 2023 Jul 21]. Available from: https://string-db.org/
   Google Scholar
• Cytoscape Version 3.10.0.| Network Data Integration, Analysis, and Visualization in a Box. [cited 2023 Jul 21]. Available from: https://cytoscape.org/
   Google Scholar
• KEGG: Kyoto Encyclopedia of Genes and Genomes. [cited 2023 Jul 21]. Available from: https://www.genome.jp/kegg/.
   Google Scholar
• ClinicalTrials.gov. Available from: https://classic.clinicaltrials.gov/ct2/home.
   Google Scholar
• Tanaka H, Yoshida M, Tanimura H, et al. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011;17(10):3272–3281. doi: 10.1158/1078-0432.CCR-10-2882
   PubMed Web of Science ®Google Scholar
• Blagden S, Omlin A, Josephs D, et al. First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer. Clin Cancer Res. 2014;20(23):5908–5917.
   PubMed Web of Science ®Google Scholar
• Tosca EM, Borella E, Piana C, et al. Model-based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2-positive advanced or metastatic breast cancer patients. CPT Pharmacometrics Syst Pharmacol. 2023;12(11):1626–1639. doi: 10.1002/psp4.12910
   PubMedGoogle Scholar
• Guillermet-Guibert J. Methods for the prophylactic treatment of cancer in patients suffering from pancreatitis using PI3Kα inhibitors. World Patent WO 2021/001427 A1. published 2021 Jan 7.
   Google Scholar
• Doukas J, Wrasidlo W, Noronha G, et al. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl Acad Sci USA. 2006;103(52):19866–19871.
   PubMed Web of Science ®Google Scholar
• Song C, Bae Y, Jun J, et al. Identification of TG100-115 as a new and potent TRPM7 kinase inhibitor, which suppresses breast cancer cell migration and invasion. Biochim Biophys Acta Gen Subj. 2017;1861(4):947–957. doi: 10.1016/j.bbagen.2017.01.034
   PubMed Web of Science ®Google Scholar
• Mishra R, Yuan L, Patel H, et al. Phosphoinositide 3-kinase (PI3K) reactive oxygen species (ROS)-activated prodrug in combination with anthracycline impairs PI3K signaling, increases DNA damage response and reduces breast cancer cell growth. Int J Mol Sci. 2021;22(4):2088. doi: 10.3390/ijms22042088
   PubMed Web of Science ®Google Scholar
• Westhoff MA, Kandenwein JA, Karl S, et al. The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair. Oncogene. 2009;28(40):3586–3596. doi: 10.1038/onc.2009.215
   PubMed Web of Science ®Google Scholar
• Patel H, Mishra R, Wier A, et al. RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells. Anticancer Drugs. 2023;34(4):519–531. doi: 10.1097/CAD.0000000000001500
   PubMed Web of Science ®Google Scholar
• Zhu H, Mishra R, Yuan L, et al. Oxidative cyclization-induced activation of a phosphoinositide 3-kinase inhibitor for enhanced selectivity of cancer chemotherapeutics. ChemMedchem. 2019;14(22):1933–1939. doi: 10.1002/cmdc.201900481
   PubMed Web of Science ®Google Scholar
• Luo L, Zhong Q, Guo S, et al. Development of a bioavailable boron-containing PI-103 bioisostere, PI-103BE. Bioorg Med Chem Lett. 2020;30(14):127258. doi: 10.1016/j.bmcl.2020.127258
   PubMed Web of Science ®Google Scholar
• Sutherlin DP, Bao L, Berry M, et al. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem. 2011;54(21):7579–7587. doi: 10.1021/jm2009327
   PubMed Web of Science ®Google Scholar
• Omeljaniuk WJ, Krętowski R, Ratajczak-Wrona W, et al. Novel dual PI3K/mTOR inhibitor, apitolisib (GDC-0980), inhibits growth and induces apoptosis in human glioblastoma cells. Int J Mol Sci. 2021;22(21):11511. doi: 10.3390/ijms222111511
   PubMed Web of Science ®Google Scholar
• Makker V, Recio FO, Ma L, et al. A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). Cancer. 2016;122(22):3519–3528. doi: 10.1002/cncr.30286
   PubMed Web of Science ®Google Scholar
• Dolly SO, Wagner AJ, Bendell JC, et al. Phase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2016;22(12):2874–2884. doi: 10.1158/1078-0432.CCR-15-2225
   PubMed Web of Science ®Google Scholar
• Powles T, Lackner MR, Oudard S, et al. Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2016;34(14):1660–1668. doi: 10.1200/JCO.2015.64.8808
   PubMed Web of Science ®Google Scholar
• Johnson F, Frederick MJ, Treatment of squamous cell carcinoma with phosphatidylinositol 3-kinase (PI3K) inhibitors. United States Patent US 2020/0248273 A1. published 2020 Aug 6.
   Google Scholar
• Maddocks ODK, Young T, Goncalves MD, Combination therapy for PIK3CA-associated diseases or disorders. World Patent WO 2023/070023 Al. published 2023 April 27.
   Google Scholar
• Gunst JD, Kjær K, Olesen R, et al. Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation. J Virus Erad. 2019;5(3):133–137. doi: 10.1016/S2055-6640(20)30042-X
   PubMed Web of Science ®Google Scholar
• Huegel J, Dinh CT, Martinelli M, et al. CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 schwannoma cells. Oncotarget. 2022;13(1):890–904. doi: 10.18632/oncotarget.28254
   PubMedGoogle Scholar
• Chen J, Guanizo AC, Jakasekara WSN, et al. MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat. J Exp Clin Cancer Res. 2023;42(1):100. doi: 10.1186/s13046-023-02678-1
   PubMed Web of Science ®Google Scholar
• Liao W, Yang W, Xu J, et al. Therapeutic potential of CUDC-907 (fimepinostat) for hepatocarcinoma treatment revealed by tumor spheroids-based drug screening. Front Pharmacol. 2021;12:658197. doi: 10.3389/fphar.2021.658197
   PubMedGoogle Scholar
• Landsburg DJ, Barta SK, Ramchandren R, et al. Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses. Br J Haematol. 2021;195(2):201–209. doi: 10.1111/bjh.17730
   PubMed Web of Science ®Google Scholar
• Barkund S, Zhou H, Friedman L, et al., Uses of glucocorticoid receptor (GR) antagonist, antiandrogen, and AKT inhibitor/PI3K inhibitor/mTOR inhibitor combinations. World Patent WO 2022/192182 A2. published 2022 Sept 15.
   Google Scholar
• Fairhurst RA, Furet P, Imbach-Weese P, et al. Identification of NVP-CLR457 as an orally bioavailable non-cns-penetrant pan-class ia phosphoinositol-3-kinase inhibitor. J Med Chem. 2022;65(12):8345–8379. doi: 10.1021/acs.jmedchem.2c00267
   PubMed Web of Science ®Google Scholar
• Harding JJ, Bauer TM, Tan DSW, et al. Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor. Invest New Drugs. 2019;37(2):271–281. doi: 10.1007/s10637-018-0627-4
   PubMed Web of Science ®Google Scholar
• Wang W, Liao L, Wang Y, et al. Preclinical evaluation of novel PI3K/mTOR dual inhibitor SN202 as potential anti-renal cancer agent. Cancer Biol Ther. 2018;19(11):1015–1022. doi: 10.1080/15384047.2018.1470733
   PubMed Web of Science ®Google Scholar
• Beaufils F, Cmiljanovic N, Cmiljanovic V, et al. 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor as clinical candidate in oncology. J Med Chem. 2017;60(17):7524–7538. doi: 10.1021/acs.jmedchem.7b00930
   PubMed Web of Science ®Google Scholar
• Collins GP, Eyre TA, Schmitz-Rohmer D, et al. A phase II study to assess the safety and efficacy of the dual mTORC1/2 and PI3K inhibitor bimiralisib (PQR309) in relapsed, refractory lymphoma. Hemasphere. 2021;5(11):e656. doi: 10.1097/HS9.0000000000000656
   PubMed Web of Science ®Google Scholar
• Johnson FM, Janku F, Gouda MA, et al. Inhibition of the phosphatidylinositol-3 kinase pathway using bimiralisib in loss-of-function NOTCH1-mutant head and neck cancer. Oncology. 2022;27(12):1004–e926. doi: 10.1093/oncolo/oyac185
   Google Scholar
• Rolli M, Schmitz-Rohmer D, Fabbro D, et al. Treatment of squamous cell carcinoma. World Patent WO2020030708. 2019 Aug 7.
   Google Scholar
• Sabbah DA, Vennerstrom JL, Zhong HA. Binding selectivity studies of phosphoinositide 3-kinases using free energy calculations. J Chem Inf Model. 2012;52(12):3213–3224. doi: 10.1021/ci3003057
   PubMed Web of Science ®Google Scholar
• Al Hasan M, Sabirianov M, Redwine G, et al. Binding and selectivity studies of phosphatidylinositol 3-kinase (PI3K) inhibitors. J Mol Graph Model. 2023 Jun;121:108433. doi: 10.1016/j.jmgm.2023.108433
   PubMed Web of Science ®Google Scholar
• Borsari C, Wymann M Method for identifying PI3 kinase-α inhibitors. World Patent WO 2022/214703 A2. published 2022 Oct 13.
   Google Scholar
• St. Jean JD. Compounds that inhibit PI3K isoform alpha and methods for treating cancer. World Patent WO 2023/018636 Al. published 2023 Feb 16.
   Google Scholar
• Chang KY, Tsai SY, Wu CM, et al. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin Cancer Res. 2011;17(22):7116–7126. doi: 10.1158/1078-0432.CCR-11-0796
   PubMed Web of Science ®Google Scholar
• Simioni C, Cani A, Martelli AM, et al. The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. Oncotarget. 2015;6(19):17147–17160. doi: 10.18632/oncotarget.3940
   PubMedGoogle Scholar
• Glienke W, Maute L, Wicht J, et al. The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates survivin gene expression in human pancreatic cancer cell lines. Tumour Biol. 2012;33(3):757–765. doi: 10.1007/s13277-011-0290-2
   PubMed Web of Science ®Google Scholar
• Wang L, Che Y, Yijing L, et al. Pharmaceutical combination comprising abemaciclib and a PI3K and/or a mtor inhibitor for the treatment of mantle cell lymphoma. World Patent WO 2023/114225 A1. published 2023 June 22
   Google Scholar
• Cheng H, Li C, Bailey S, et al. Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04979064 through structure-based drug design. ACS Med Chem Lett. 2013;4(1):91–97. doi: 10.1021/ml300309h
   PubMed Web of Science ®Google Scholar
• Han J, Chen Y, Yang C, et al. Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor. Eur J Med Chem. 2016;122:684–701. doi: 10.1016/j.ejmech.2016.06.030
   PubMed Web of Science ®Google Scholar
• Choi HJ, Heo JH, Park JY, et al. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer. Gynecol Oncol. 2019;153(1):135–148. doi: 10.1016/j.ygyno.2019.01.012
   PubMed Web of Science ®Google Scholar
• Kim MN, Lee SM, Kim JS, et al. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma. Cancer Chemother Pharmacol. 2019;84(4):809–817. doi: 10.1007/s00280-019-03918-y
   PubMed Web of Science ®Google Scholar
• Kim MY, Kruger AJ, Jeong JY, et al. Combination therapy with a PI3K/mTOR dual inhibitor and chloroquine enhances synergistic apoptotic cell death in Epstein-Barr virus-infected gastric cancer cells. Mol Cells. 2019;42(6):448–459.
   PubMed Web of Science ®Google Scholar
• Hanan EJ, Braun MG, Heald RA, et al. Discovery of GDC-0077 (inavolisib), a highly selective inhibitor and degrader of mutant PI3Kα. J Med Chem. 2022;65(24):16589–16621. doi: 10.1021/acs.jmedchem.2c01422
   PubMed Web of Science ®Google Scholar
• Song KW, Edgar KA, Hanan EJ, et al. RTK-dependent inducible degradation of mutant PI3Kα drives GDC-0077 (inavolisib) efficacy. Cancer Discov. 2022;12(1):204–219. doi: 10.1158/2159-8290.CD-21-0072
   PubMed Web of Science ®Google Scholar
• Vasan N, Baselga J Biomarkers for determining responsiveness of a cancer to phosphatidylinositol 3-kinase (PI3K) inhibitors. World Patent WO 2020/041684 A1. published 2020 Feb 27.
   Google Scholar
• Hong DS, Postow M, Chmielowski B, et al. Eganelisib, a first-in-class PI3Kγ inhibitor, in patients with advanced solid tumors: results of the phase 1/1b MARIO-1 trial. Clin Cancer Res. 2023;29(12):2210–2219. doi: 10.1158/1078-0432.CCR-22-3313
   PubMed Web of Science ®Google Scholar
• Faehling S, Coelho M, Floerchinger A, et al. Simultaneous inhibition of PI3Kgamma and PI3Kdelta deteriorates T-cell function with implications for chronic lymphocytic leukemia. Hemasphere. 2023 Mar;7(3):e840. doi: 10.1097/HS9.0000000000000840
   PubMed Web of Science ®Google Scholar
• Xu Y, Afify SM, Du J, et al. The efficacy of PI3Kγ and EGFR inhibitors on the suppression of the characteristics of cancer stem cells. Sci Rep. 2022;12(1):347. doi: 10.1038/s41598-021-04265-w
   PubMed Web of Science ®Google Scholar
• Sun D, Gao W, Wen F, et al. PI3K inhibitors, nanoformulations, and uses thereof. World Patent WO 2022/226052 A1. published 2022 Oct 27.
   Google Scholar
• O´connell BC Eganelisib for use in the treatment of PD-L1 negative cancer. World Patent WO 2022/125497 A1. published 2022 June 16.
   Google Scholar
• Kong D, Yamori T. Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci. 2008;99(9):1734–1740. doi: 10.1111/j.1349-7006.2008.00891.x
   PubMed Web of Science ®Google Scholar
• Azzi J, Moore RF, Elyaman W, et al. The novel therapeutic effect of phosphoinositide 3-kinase-γ inhibitor AS605240 in autoimmune diabetes. Diabetes. 2012;61(6):1509–1518. doi: 10.2337/db11-0134
   PubMed Web of Science ®Google Scholar
• Sun J, Cai G, Shen J, et al. AS-605240 blunts osteoporosis by inhibition of bone resorption. Drug Des Devel Ther. 2023;17:1275–1288. doi: 10.2147/DDDT.S403231
   PubMed Web of Science ®Google Scholar
• Li M, Sala V, De Santis MC, et al. Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth. Circulation. 2018;138(7):696–711. doi: 10.1161/CIRCULATIONAHA.117.030352
   PubMed Web of Science ®Google Scholar
• Kong W, Sender S, Taher L, et al. BTK and PI3K inhibitors reveal synergistic inhibitory anti-tumoral effects in canine diffuse large b-cell lymphoma cells. Int J Mol Sci. 2021;22(23):12673. doi: 10.3390/ijms222312673
   PubMed Web of Science ®Google Scholar
• Gao B, Wang L, Zhang N, et al. Screening novel drug candidates for kidney renal clear cell carcinoma treatment: a study on differentially expressed genes through the connectivity map database. Kidney Blood Press Res. 2021;46(6):702–713. doi: 10.1159/000518437
   PubMedGoogle Scholar
• Alluri R, Ambati SR, Routhu K, et al. Phosphoinositide 3-kinase inhibitor AS605240 ameliorates streptozotocin-induced Alzheimer’s disease like sporadic dementia in experimental rats. EXCLI J. 2020;19:71–85. doi: 10.17179/excli2019-1997
   PubMed Web of Science ®Google Scholar
• Garces AE, Stocks MJ. Class 1 PI3K clinical candidates and recent inhibitor design strategies: a medicinal chemistry perspective. J Med Chem. 2019;62(10):4815–4850. doi: 10.1021/acs.jmedchem.8b01492
   PubMed Web of Science ®Google Scholar
• Ali AY, Wu X, Eissa N, et al. Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration. Leukemia.2018 Sep;32(9):1958–1969.
   PubMed Web of Science ®Google Scholar
• Piddock RE, Loughran N, Marlein CR, et al. PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment. Blood Cancer J. 2017 Mar 10;7(3):e539. doi: 10.1038/bcj.2017.16
   PubMedGoogle Scholar
• Wang Z, Hao Y, Li Y Compositions and methods of treating PIK3CA helical domain mutant cancers. United States Patent US 2022/0193056 A1. published 2022 June 23
   Google Scholar
• Pemberton N, Mogemark M, Arlbrandt S, et al. Discovery of highly isoform selective orally bioavailable phosphoinositide 3-kinase (PI3K)-γ inhibitors. J Med Chem. 2018;61(12):5435–5441. doi: 10.1021/acs.jmedchem.8b00447
   PubMed Web of Science ®Google Scholar
• Carnevalli LS, Taylor MA, King M, et al. Macrophage activation status rather than repolarization is associated with enhanced checkpoint activity in combination with PI3Kγ inhibition. Mol Cancer Ther. 2021;20(6):1080–1091. doi: 10.1158/1535-7163.MCT-20-0961
   PubMed Web of Science ®Google Scholar
• Safina BS, Sweeney ZK, Li J, et al. Identification of GNE-293, a potent and selective PI3Kδ inhibitor: navigating in vitro genotoxicity while improving potency and selectivity. Bioorg Med Chem Lett. 2013;23(17):4953–4959. doi: 10.1016/j.bmcl.2013.06.052
   PubMed Web of Science ®Google Scholar
• Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058–2070.
   PubMed Web of Science ®Google Scholar
• Shi Z, Wulfkuhle J, Nowicka M, et al. Functional mapping of AKT signaling and biomarkers of response from the FAIRLANE trial of neoadjuvant ipatasertib plus paclitaxel for triple-negative breast cancer. Clin Cancer Res. 2022;28(5):993–1003. doi: 10.1158/1078-0432.CCR-21-2498
   PubMed Web of Science ®Google Scholar
• Spencer A, Yoon SS, Harrison SJ, et al. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014;124(14):2190–2195. doi: 10.1182/blood-2014-03-559963
   PubMed Web of Science ®Google Scholar
• Ragon BK, Odenike O, Baer MR, et al. Oral MEK 1/2 inhibitor trametinib in combination with AKT inhibitor GSK2141795 in patients with acute myeloid leukemia with RAS mutations: a phase II study. Clin Lymphoma Myeloma Leuk. 2019;19(7):431–40.e13. doi: 10.1016/j.clml.2019.03.015
   PubMed Web of Science ®Google Scholar
• Levy DS, Kahana JA, Kumar R. AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood. 2009;113(8):1723–1729. doi: 10.1182/blood-2008-02-137737
   PubMed Web of Science ®Google Scholar
• Weisner J, Gontla R, van der Westhuizen L, et al. Covalent-allosteric kinase inhibitors. Angew Chem Int Ed Engl. 2015;54(35):10313–10316. doi: 10.1002/anie.201502142
   PubMed Web of Science ®Google Scholar
• Hirai H, Sootome H, Nakatsuru Y, et al. MK-2206, an allosteric akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010;9(7):1956–1967. doi: 10.1158/1535-7163.MCT-09-1012
   PubMed Web of Science ®Google Scholar
• Deng X Inhibitors of MCL-1 domain and AKT domain interaction and uses thereof for the treatment of cancer. United States Patent US20210137953A1. published 2021 May 13
   Google Scholar
• Huang J, Chen L, Wu J, et al. Targeting the PI3K/AKT/mTOR signaling pathway in the treatment of human diseases: current status, trends, and solutions. J Med Chem. 2022 Dec 22;65(24):16033–16061. doi: 10.1021/acs.jmedchem.2c01070
   PubMed Web of Science ®Google Scholar
• Howell SJ, Casbard A, Carucci M, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol. 2022 Jul;23(7):851–864.
   PubMed Web of Science ®Google Scholar
• Crabb SJ, Griffiths G, Marwood E, et al. Pan-AKT Inhibitor capivasertib with docetaxel and prednisolone in metastatic castration-resistant prostate cancer: A randomized, placebo-controlled phase ii trial (ProCAID). J Clin Oncol. 2021 Jan 20;39(3):190–201. doi: 10.1200/JCO.20.01576
   PubMed Web of Science ®Google Scholar
• Floch N, Martin M, Joseph S, et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for the treatment of cancer. World Patent WO 2023/187037 A1, published 2023 Oct 5.
   Google Scholar
• Turner N, Dent RA, O’Shaughnessy J, et al. Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast Cancer Res Treat. 2022;191(3):565–576. doi: 10.1007/s10549-021-06450-x
   PubMed Web of Science ®Google Scholar
• Sweeney C, Bracarda S, Sternberg CN, et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2021;398(10295):131–142. doi: 10.1016/S0140-6736(21)00580-8
   PubMed Web of Science ®Google Scholar
• Withana NP, Mani A, Singel SM Treatment of breast cancer using combination therapies comprising an AKT inhibitor, a taxane, and a PD-l1 inhibitor. World Patent WO 2020/131765 A1. published 2020 Jun 25.
   Google Scholar
• Gray N, You I, Zhang T Degradation of AKT by conjugation of ATP-competitive AKT inhibitor GDC-0068 with E3 ligase ligands and methods of use. World Patent WO 2020/0226481 A1. published 2020 Oct 15.
   Google Scholar
• Lu C, Zhang R, Yu Y, et al. Methods of treating prostate cancer in a patient using combination of afuresertib and CFG920. World Patent WO 2021/026454 A1, published 2021 Feb 11.
   Google Scholar
• Wee S, Jagani Z, Xiang KX, et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 2009;69(10):4286–4293. doi: 10.1158/0008-5472.CAN-08-4765
   PubMed Web of Science ®Google Scholar
• Liu JF, Gray KP, Wright AA, et al. Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. Gynecol Oncol. 2019;154(1):95–101. doi: 10.1016/j.ygyno.2019.05.003
   PubMed Web of Science ®Google Scholar
• Shen Z, Kin K AKT inhibitor in combination with PIM kinase inhibitor. World Patent WO 2023/202563 A1. published 2023 Oct 26.
   Google Scholar
• Ma C, Wu J, Wang L, et al. Discovery of clinical candidate NTQ1062 as a potent and bioavailable akt inhibitor for the treatment of human tumors. J Med Chem. 2022;65(12):8144–8168. doi: 10.1021/acs.jmedchem.2c00527
   PubMed Web of Science ®Google Scholar
• Che J, Dai X, Gao J, et al. Discovery of N-((3S,4S)-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1H-pyrazol-5-yl)benzamide (Hu7691), a potent and selective Akt inhibitor that enables decrease of cutaneous toxicity. J Med Chem. 2021;64(16):12163–12180. doi: 10.1021/acs.jmedchem.1c00815
   PubMed Web of Science ®Google Scholar
• Landel I, Quambusch L, Depta L, et al. Spotlight on AKT: Current therapeutic challenges. ACS Med Chem Lett. 2020;11(3):225–227. doi: 10.1021/acsmedchemlett.9b00548
   PubMed Web of Science ®Google Scholar
• Chien AJ, Tripathy D, Albain KS, et al. MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2-positive and/or hormone receptor-negative breast cancers in the I-SPY 2 trial. J Clin Oncol. 2020;38(10):1059–1069.
   PubMed Web of Science ®Google Scholar
• Murphy AG, Zahurak M, Shah M, et al. A Phase I study of dinaciclib in combination with MK-2206 in patients with advanced pancreatic cancer. Clin Transl Sci. 2020;13(6):1178–1188. doi: 10.1111/cts.12802
   PubMed Web of Science ®Google Scholar
• Wood K, Lin KH, Rutter J, et al. Compositions and methods for sensitizing acute myeloid leukemias to chemotherapy. World Patent WO 2021/242859 A1. published 2021 Dec 2.
   Google Scholar
• Yu Y, Savage RE, Eathiraj S, et al. Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092. PLoS One. 2015;10(10):e0140479. doi: 10.1371/journal.pone.0140479
   PubMed Web of Science ®Google Scholar
• Le Cras TD, Goines J, Lakes N, et al. Constitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation. Angiogenesis. 2020;23(3):425–442. doi: 10.1007/s10456-020-09722-0
   PubMed Web of Science ®Google Scholar
• Biesecker LG, Edwards M, O’Donnell S, et al. Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092). Cold Spring Harb Mol Case Stud. 2020;6(1):a004549. doi: 10.1101/mcs.a004549
   PubMed Web of Science ®Google Scholar
• Taunton J, Craven GB, Reisberg SH, et al. Preparation of substituted 3-(imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines as covalent modifiers of AKT1 and uses thereof. World Patent WO 2023/168291 A1. published 2023 Sept 7.
   Google Scholar
• Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327(5971):1345–1350. doi: 10.1126/science.1177319
   PubMed Web of Science ®Google Scholar
• Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov. 2017;16(2):101–114. doi: 10.1038/nrd.2016.211
   PubMed Web of Science ®Google Scholar
• Xu J, Yu X, Martin TC, et al. AKT degradation selectively inhibits the growth of PI3K/PTEN pathway-mutant cancers with wild-type KRAS and BRAF by destabilizing aurora kinase B. Cancer Discov. 2021;11(12):3064–3089.
   PubMed Web of Science ®Google Scholar
• You I, Erickson EC, Donovan KA, et al. Discovery of an AKT Degrader with prolonged inhibition of downstream signaling. Cell Chem Biol. 2020;27(1):66–73.e7. doi: 10.1016/j.chembiol.2019.11.014
   PubMed Web of Science ®Google Scholar
• He M, Cao C, Ni Z, et al. Protacs: great opportunities for academia and industry (an update from 2020 to 2021). Signal Transduct Target Ther. 2022;7(1):181. doi: 10.1038/s41392-022-00999-9
   PubMed Web of Science ®Google Scholar
• Yu X, Xu J, Cahuzac KM, et al. Novel allosteric inhibitor-derived AKT proteolysis targeting chimeras (PROTACs) enable potent and selective AKT degradation in KRAS/BRAF mutant cells. J Med Chem. 2022;65(20):14237–14260. doi: 10.1021/acs.jmedchem.2c01454
   PubMed Web of Science ®Google Scholar
• Jauslin WT, Schild M, Schaefer T, et al. A high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3Kα. Chem Sci. 2024;15(2):683–691. doi: 10.1039/d3sc04629j
   PubMed Web of Science ®Google Scholar
• Sabbah DA, Simms NA, Brattain MG, et al. Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases. Bioorg Med Chem Lett. 2012;22(2):876–880.
   PubMed Web of Science ®Google Scholar
• Cantley LC, Hopkins B, Mukherjee S, et al. Combination therapy for PI3K-associated disease or disorder. World Patent WO 2019/232403 Al. published 2019 Dec 5.
   Google Scholar
• Zhong HA, Goodwin DT. Selectivity studies and free energy calculations of AKT inhibitors. Molecules. 2024;29(6):1233. doi: 10.3390/molecules29061233
   PubMed Web of Science ®Google Scholar
• Schmid P, Turner NC, Barrios CH, et al. First-line ipatasertib, atezolizumab, and taxane triplet for metastatic triple-negative breast cancer: clinical and biomarker results. Clin Cancer Res. 2024;30(4):767–778. doi: 10.1158/1078-0432.CCR-23-2084
   PubMed Web of Science ®Google Scholar